Desensitization to lenalidomide in a patient with relapsed multiple myeloma.

@article{Seki2013DesensitizationTL,
  title={Desensitization to lenalidomide in a patient with relapsed multiple myeloma.},
  author={Jack Toshimine Seki and Sabiha Banglawala and Emily M Lentz and Donna E. Reece},
  journal={Clinical lymphoma, myeloma & leukemia},
  year={2013},
  volume={13 2},
  pages={162-5}
}
Introduction Lenalidomide belongs to a class of immunomodulatory drugs that represents a promising advancement in the treatment of multiple myeloma (MM). An oral structural analogue of thalidomide, lenalidoide was developed to produce an agent with a more favorable toxicity rofile than that of its parent drug. Initially approved in 2005 for the reatment of transfusion-dependent anemia caused by lowto interme- 
3 Citations
17 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Pharmacological properties of thalidomide and its analogues

  • JB De Sanctis, M Mijares, A Suárez
  • Recent Pat Inflamm Allergy Drug Discov
  • 2010
1 Excerpt

Managementofpatientswithchronic lymphocytic leukemia treated with lenalidomide

  • MusialL MillerKC, WhitworthA
  • Clin Lymphoma Myeloma
  • 2008

Similar Papers

Loading similar papers…